P rotein kinase C (PKC) exists as a family of serine/ From the Aab
threonine kinases in which 9 different isoforms have been cloned and characterized. 1 The conventional PKC isoforms, ␣, ␤, and ␥, are distinguished by C1 and C2 binding domains in the amino terminal regulatory region of the protein. The C1 domain provides a diacylglycerol/ phorbol ester-binding motif, whereas the C2 domain binds anionic phospholipids in a Ca 2ϩ -dependent fashion. 2 Such features render conventional PKCs subject to downstream modulation by a myriad of receptors that couple to activation of phospholipase C, including G-protein-coupled receptors, growth factor receptors, and adhesion receptors. Indeed, there are established and putative roles for PKCs in multiple physiological and pathological conditions. 3 Specific interest in PKC␣ regulation of cardiac function stems from several important findings in small animal studies. For example, transgenic myocardial expression of activated PKC␣ impaired ␤-AR signaling and cardiac contractility in mice. 4 Moreover, genetic deletion of PKC␣ protected against pressure-overload heart failure (HF) and dilated cardiomyopathy in separate mouse models. 5 Adenoviral delivery of dominant-negative PKC␣ also reversed HF progression in a rat cryoinfarct model, 6 supplying concordant evidence for cardioprotection by means of PKC␣ inhibition. Finally, pharmacological inhibition of conventional PKCs in wild-type and double-null PKC␤␥ Ϫ/Ϫ mice improved survival and heart function after transverse aortic constriction, 7 suggesting that PKC␣ may be the primary isoform to target in HF therapy. Together, these studies provide a compelling rationale to launch investigations into whether such findings can be corroborated in large-animal models that more closely resemble human physiology.
In the current issue of Circulation Research, Ladage et al report the first study showing that PKC␣/␤ inhibition with ruboxistaurin attenuates post-myocardial infarction HF in pigs. 8 Pigs weighing 20 kg were subjected to 90-minute balloon occlusion of the left anterior descending artery, yielding an average infarct size of Ϸ15% of the left ventricle. Animals were subsequently assigned to receive control chow or ruboxistaurin-containing chow (10 mg/kg per day) for 12 weeks. Echocardiography assessment of heart function revealed significantly improved ejection fraction and cardiac output 3 months after injury. At the same time point, hemodynamic data also showed normalization of peak left ventricular pressure rate of rise with ruboxistaurin treatment. Curiously, these cardiac functional parameters were relatively similar between the vehicle and ruboxistaurin groups at earlier time points (2 days, 1 month, and 2 months after myocardial infarction). Regardless, the work of Ladage et al is an encouraging step toward justifying the clinical use of ruboxistaurin for HF therapy.
The established safety profile of ruboxistaurin in clinical trials for diabetic retinopathy and microvasculopathy 9,10 is an auspicious feature of the compound that supports its further investigation in cardiac disease. It also highlights a remaining question in the present work: What is the mechanism by which ruboxistaurin attenuates HF progression in this porcine model (Figure) ? Ruboxistaurin is often cited as a PKC␤-isozyme-selective inhibitor, [11] [12] [13] [14] particularly in the setting of diabetic retinopathy. 15 Furthermore, PKC␣ has been implicated in regulating angiogenesis, 16 metastasis, 17 endothelial permeability, 18 platelet aggregation, 19 thrombus formation, 20 and inflammatory cell adhesion. 21 Thus, the newly demonstrated efficacy of ruboxistaurin in treating HF may depend, at least in part, on broad cardiac and extracardiac PKC␣/␤ modulation.
The authors aimed to establish a specific mechanism of action for ruboxistaurin by immunoblot analysis of a host of myocardial proteins but found no significant differences in expression/activation between the 2 treatment groups; nor was there any overt evidence of alterations in cardiac histopathology or ventricular remodeling with ruboxistaurin. One may expect enhanced contractility on PKC inhibition to present rather quickly, as previously reported in small animals. 6, 22 Moreover, data indicating the efficacy or level of PKC inhibition in the pig are not presented. It is suggested that potential beneficial effects of ruboxistaurin on heart geometry might need more time to manifest. Certainly the power of the findings would be augmented by confirmation with a larger number of animals over a greater experimental duration. These experiments may require a different large-animal model, considering that the rapid growth phase of the young pigs at later time points may cloud interpretation. Such concerns, however, should not detract from the significance of the present communication. HF continues to be a costly and debilitating health concern worldwide, and Ladage et al are to be commended for this vital contribution validating a potential novel HF therapeutic in a large-animal model. Future experiments evaluating additional doses of ruboxistaurin may provide critical mechanistic and functional insight, and comparative efficacy experiments with current standard HF therapies will further bolster the case for clinical trials. The precise mechanism of ruboxistaurin cardioprotection could be obfuscated by broad distribution of PKCs as well as coexpression of multiple PKC isoforms in the same cell type. However, this may prove advantageous, considering the possibility that comprehensive PKC regulation may evoke mutually salubrious results at multiple sites throughout the body. 
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Figure.
Possible mechanism(s) of ruboxistaurin-mediated heart failure antagonism in cardiac myocytes. PKC ␣/␤ are activated downstream of G q -coupled, G-protein-coupled receptor signaling and intracellular Ca 2ϩ . PKC ␣/␤ phosphorylation targets include troponin I and troponin T (TnI/TnT), as well as the protein inhibitor I-1. Phosphorylation of TnI/TnT dampens myofilament Ca 2ϩ sensitivity and developed tension. 23 I-1 phosphorylation removes inhibition of protein phosphatase-1 (PP-1), promoting dephosphorylation of phospholamban (PLB), and reduction of sarcoplasmic reticulum (SR) Ca 2ϩ ATPase activity. 5 The net result of PKC ␣/␤ activation is impaired SR Ca 2ϩ load, Ca 2ϩ transients, and contractility. Thus, blockade of PKC ␣/␤ with ruboxistaurin may enhance pig heart contractility in vivo. 8 
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